Clinical trial for Alzheimer Disease
Official title Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
ClinicalTrials.gov ID: NCT06511752
What this study is testing
- What it's testing
- The current study aims to examine the benefits of an education/support group program for individuals with progressive aphasia (caused by various etiologies, diagnoses) and their carepartners.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older. Healthy volunteers may be eligible.
You may be able to join if
- speak Spanish and/or English (although participants may speak other languages in addition to Spanish and/or English)
- identify as Hispanic and/or Latinx,
- or their spouse/family member with PA identifies as Hispanic and/or Latinx
- see and hear well enough to participate
- have access to a computer or mobile device with video capability
You likely can't join if
- Beyond the inclusion criteria included above, no additional exclusion criteria apply
See the full eligibility criteria
- speak Spanish and/or English (although participants may speak other languages in addition to Spanish and/or English)
- identify as Hispanic and/or Latinx,
- or their spouse/family member with PA identifies as Hispanic and/or Latinx
- see and hear well enough to participate
- have access to a computer or mobile device with video capability
- Has a diagnosis of PA, or language-led dementia, and aphasia is one of the primary causes of difficulty with activities of daily living
- Aware of language difficulties and willing to discuss them
- Able to actively engage in group discussion and complete activities with minimal support
- Able to regularly attend meetings
- Diagnosis of aphasia or dementia that is progressive in nature, and aphasia is one of the primary causes of difficulty with activities of daily living
- Have some ability to communicate and understand communication in order to participate in training sessions
- Are functionally able to engage in training sessions (e.g., able to maintain some attention, minimal challenging behavior that would cause disruption)
- Have a care partner who also consents to participating in the project
- Self-identification as a caregiver of an individual with a diagnosis of PA or language-led dementia
- Willing to discuss caregiving for individuals with PA/ language-led dementia
- Able to regularly attend meetings
- Willing to follow the rules of the support group for interacting with others respectfully
- Beyond the inclusion criteria included above, no additional exclusion criteria apply
The study team makes the final eligibility decision.
Where it is enrolling
- Austin, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Austin, Texas, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.